Get the Stockscreener App
81.56
0.17%
-0.14
After Hours:
81.56
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $81.56, with a volume of 2.62M.
It is down -0.17% in the last 24 hours and up +10.89% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$81.70
Open:
$80.73
24h Volume:
2.62M
Relative Volume:
0.62
Market Cap:
$252.95B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
30.44
EPS:
2.6798
Net Cash Flow:
$8.49B
1W Performance:
+2.08%
1M Performance:
+10.89%
6M Performance:
+5.24%
1Y Performance:
-1.79%
1-Day Range:
$80.18
$81.61
1-Week Range:
$79.43
$82.41
52-Week Range:
$61.24
$83.43
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
81.56 | 253.31B | 56.53B | 8.32B | 8.49B | 2.6798 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term - Yahoo Finance
What's Going On With AstraZeneca Stock Monday?AstraZeneca (NASDAQ:AZN) - Benzinga
AstraZeneca’s Tagrisso combination shows survival benefit in lung cancer trial - Clinical Trials Arena
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial - MarketScreener
AstraZeneca’s New CKD Study: A Strategic Move in the Chinese Market - MSN
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Reports Significant Survival Improvement in Phase 3 Trial - MarketScreener
AstraZeneca Reports Record Life Extension in Lung Cancer - bgnes.com
AstraZeneca says Flaura2 final overall survival analysis reinforces favourable benefit-risk profile of this combination - MarketScreener
Astra’s Lung Cancer Combination Boosted Survival in Key Study - Bloomberg.com
Can machine learning forecast AstraZeneca PLC Depositary Receipt recovery2025 Dividend Review & Free Real-Time Market Sentiment Alerts - Newser
Detecting price anomalies in AstraZeneca PLC Depositary Receipt with AIWeekly Investment Recap & Capital Efficient Trading Techniques - Newser
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca's (LON:AZN) investors will be pleased with their notable 61% return over the last five years - Yahoo Finance
Goldman Sachs Remains Bullish on AstraZeneca (AZN) - Yahoo Finance
Relative strength of AstraZeneca PLC Depositary Receipt in sector analysisMarket Growth Report & Weekly Top Gainers Trade List - Newser
Is AstraZeneca PLC Depositary Receipt a defensive stockJuly 2025 Intraday Action & High Conviction Buy Zone Alerts - خودرو بانک
What does recent volatility data suggest for AstraZeneca PLC Depositary Receipt2025 Geopolitical Influence & Smart Money Movement Tracker - Newser
AstraZeneca PLC's (LON:AZN) Stock Is Going Strong: Is the Market Following Fundamentals? - simplywall.st
Will AstraZeneca PLC Depositary Receipt price bounce be sustainableBond Market & Community Shared Stock Ideas - Newser
AstraZeneca, Corning And More On CNBC's 'Final Trades' - Benzinga
What momentum shifts mean for AstraZeneca PLC Depositary ReceiptTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - Newser
Analyst Downgrade: Can AstraZeneca PLC Depositary Receipt lead its sector in growthWeekly Trend Summary & Trade Opportunity Analysis Reports - خودرو بانک
Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak - Yahoo Finance
AstraZeneca PLC Depositary Receipt stock trend outlook and recovery path2025 Valuation Update & Fast Exit Strategy with Risk Control - Newser
What’s AstraZeneca PLC Depositary Receipt’s historical returnJuly 2025 Summary & Stepwise Trade Signal Guides - خودرو بانک
Is AstraZeneca PLC Depositary Receipt reversing from oversold territory2025 Winners & Losers & Low Risk Entry Point Guides - Newser
Just over £119 now, AstraZeneca’s share price looks cheap to me anywhere under £220.91 - uk.finance.yahoo.com
Published on: 2025-09-03 10:55:11 - خودرو بانک
What technical models suggest about AstraZeneca PLC Depositary Receipt’s comeback - Newser
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug - Seeking Alpha
What institutional flow reveals about AstraZeneca PLC Depositary ReceiptEntry Point & Stock Market Timing Techniques - Newser
What MACD and RSI say about AstraZeneca PLC Depositary ReceiptShare Buyback & Verified Momentum Stock Watchlist - Newser
What are AstraZeneca PLC Depositary Receipt’s recent SEC filings showingDividend Hike & AI Based Trade Execution Alerts - خودرو بانک
Verdion signs AstraZeneca to Stockholm logistics park - Green Street News
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure - Yahoo Finance
Can AstraZeneca PLC Depositary Receipt deliver alphaJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - خودرو بانک
FibroGen Completes Sale of Chinese Subsidiary to AstraZeneca - MarketScreener
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca: Buy This Pharma Star Now For Upside Potential - Seeking Alpha
Real time scanner hits for AstraZeneca PLC Depositary Receipt explainedJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - Newser
AstraZeneca Announces Current Share Capital and Voting Rights - TipRanks
AstraZeneca’s baxdrostat shows promise in Phase III hypertension trial - Clinical Trials Arena
Published on: 2025-09-01 16:47:49 - خودرو بانک
Can trapped investors hope for a rebound in AstraZeneca PLC Depositary ReceiptMarket Activity Summary & Technical Pattern Based Buy Signals - Newser
AstraZeneca Shares (LON:AZN) Higher: Strong Baxdrostat Data - AskTraders.com
AstraZeneca to seek approval for new drug which could deliver $5 billion annual sales, 1 Sep 2025 11:43 - Shares Magazine
What candlestick patterns are forming on AstraZeneca PLC Depositary ReceiptPortfolio Return Report & High Yield Equity Trading Tips - Newser
After this weekend’s news, is it time to look again at the AstraZeneca share price? - MSN
Signal strength of AstraZeneca PLC Depositary Receipt stock in tech scannersEarnings Recap Report & Long-Term Safe Investment Ideas - Newser
Multi asset correlation models including AstraZeneca PLC Depositary ReceiptPortfolio Performance Report & Reliable Entry Point Trade Alerts - Newser
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):